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Background: Patients with tuberculosis (TB) symptoms in low-resource 
settings face convoluted diagnostic and treatment linkage pathways, 
incurring substantial health-seeking costs. In the context of a 
randomised trial looking at the impact of novel diagnostics such as 
computer-aided chest x-ray diagnosis (CAD4TB), we aimed to 
investigate the costs incurred by patients seeking TB diagnosis and 
whether optimised diagnostic interventions could result in a reduction 
in the cost faced by households. 
Methods: PROSPECT was a three-arm randomised trial conducted in a 
public primary health clinic in Blantyre, Malawi during 2018-2019 (trial 
arms: standard of care [SOC]; HIV testing [HIV]; HIV testing and 
CAD4TB [HIV/TB]). The direct and indirect costs incurred by 219 
PROSPECT participants over the 56-day follow-up period were 
collected. Costs were deemed catastrophic if they exceeded 20% of 
annual household income. We compared mean costs and used 
generalised linear regression models to examine whether the 
interventions could result in a reduction in total costs. 
Results: The mean total cost incurred by all 219 participants was 
US$12.11 (standard error (SE): 1.86). The indirect and direct cost was 
US$8.47 (SE: 1.66) and US$3.64 (SE: 0.38), respectively. The mean total 
cost composed of 5.6% of the average annual household income. In 
total, 5% (9/180) of the participants with complete income data 
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incurred catastrophic costs. Compared to SOC, there was no 
statistically significant difference in the mean total cost faced by those 
in the HIV (ratio: 0.77, 95% CI: 0.51, 1.19) and HIV/TB arms (ratio: 0.85, 
95% CI: 0.53, 1.37). 
Conclusions: Despite the absence of user fees, patients seeking 
healthcare with TB symptoms incurred catastrophic costs. The 
optimised TB diagnostic interventions that were investigated in the 
PROSPECT study did not significantly reduce costs. TB diagnosis 
interventions should be implemented alongside social protection 
policies whilst ensuring healthcare facilities are accessible by the poor.
Keywords 
Tuberculosis, diagnostics and tools, health economics, catastrophic 
costs
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Introduction
Despite the current achievements made in reducing the burden 
of tuberculosis (TB), it continues to be a major public health 
problem and one of the leading causes of death world-wide1. 
During 2019, approximately 10 million new cases of TB and 
1.4 million TB-related deaths occurred globally1. Low- and 
middle-income countries (LMICs) carry a substantial pro-
portion of this burden, with at least 25% of all new TB cases 
occurring in Africa alone1.
Early diagnosis and treatment can substantially ease the cur-
rent TB disease burden. Ensuring early diagnosis and prompt 
initiation of treatment can reduce TB transmission and improve 
individual health outcomes whilst reducing disability2–5. 
However, the effectiveness of TB diagnostic interventions in 
health systems are limited as poverty and high out of pocket 
expenditure are barriers to patients seeking TB diagnosis and 
treatment in LMICs6–8.
Malawi is a low-income country and is among the 30 countries 
listed as having a high TB/HIV burden9. The public sec-
tor is the largest healthcare provider in Malawi, providing 
approximately 60% of healthcare services, the rest are pro-
vided by the private sector10. TB care is provided free of charge 
through national treatment programmes. However, due to 
resource constraints and a heavy disease burden, the TB diag-
nosis and treatment pathways are characterised by suboptimal 
diagnostic tests and convoluted treatment linkage11,12. Not only 
does this lengthen the time to diagnosis, it leads to substan-
tial care-seeking costs as patients undergo multiple visits to 
health facilities and endure extensive waiting times12–15.
Studies conducted in Malawi and other sub-Saharan African 
countries have shown that the costs incurred from seeking a 
diagnosis and the cost of treatment can become catastrophic 
for a substantial proportion of households9,14,16–19. Costs are 
considered catastrophic once they exceed 20% of the patient’s 
annual household income20. The elimination of catastrophic 
costs associated with TB is among the targets set for the year 
2020 in the End TB strategy21. This, however, is unlikely to have 
been achieved as by the end of 2019, the average proportion 
of TB-affected households facing catastrophic costs was 49%1.
Research efforts towards the identification and develop-
ment of interventions that can optimise the TB diagnostic and 
treatment pathways are urgently required21. Alongside this, 
there is a need to investigate whether such interventions can 
lead to reductions in the costs faced by patients seeking care. 
The PROSPECT trial (NCT03519425), was an open, three-arm 
pragmatic randomised trial, recently conducted in Malawi22. Its 
primary aim was to investigate the effectiveness of optimised 
HIV and TB diagnosis, and linkage to care interventions in 
reducing time to TB treatment initiation.
By surveying participants recruited to the PROSPECT trial, we 
aimed to investigate the costs faced by patients when seeking 
care with TB symptoms in Blantyre, Malawi. As the HIV and 
TB diagnostic interventions investigated in the PROSPECT 
trial aimed to reduce time to TB treatment initiation, we 
hypothesised that these interventions could result in a reduction 
in the total costs faced by households.
Methods
Study design
PROSPECT was an open, three-arm, pragmatic randomised 
trial investigating the impact of novel diagnostic and linkage 
to care interventions on improving the effectiveness of TB and 
HIV diagnosis and treatment22. We surveyed a consecutive 
sample of individuals participating in the PROSPECT trial 
to estimate the direct medical, direct non-medical and indi-
rect costs incurred by those accessing healthcare services with 
TB symptoms.
Study site and participants
The study took place at the Bangwe Health Centre in Blantyre, 
Malawi. Bangwe Health Centre is a public primary health 
care clinic located in a densely populated peri-urban area of 
Blantyre. Adult TB prevalence in Blantyre is estimated to 
be 900 per 100,000 adults23. TB diagnostic services at the clinic 
follow standard Malawi Ministry of Health guidelines24. TB 
treatment is provided at the clinic using standard TB regi-
mens. Under routine care conditions, patients with presump-
tive TB are investigated by sputum smear microscopy and/or 
GeneXpert MTB/Rif. There are no physicians at the study 
clinic; all care is provided by clinical officers and nurses. 
There are no user fees at the clinic.
Patients that were seeking care from Bangwe Health Centre 
and were at least 18 years old, with a cough of any duration, 
and not taking TB treatment or isoniazid preventative therapy 
were eligible for recruitment to the PROSPECT Study. These 
participants were randomly allocated in a 1:1:1 ratio into one 
of three trial groups: standard of care (SOC arm); optimised 
HIV screening and linkage to care (HIV arm); and optimised 
TB and HIV screening and linkage to care (HIV/TB arm).
Study procedures have been described previously22. In brief, 
participants in the SOC arm underwent clinician-directed 
TB and HIV screening and linkage to care, without input from 
the study team. In the HIV arm, participants were offered 
oral HIV testing, confirmatory study finger-prick HIV testing 
and linkage to antiretroviral therapy (ART) treatment 
services, with TB screening directed by the routine clinic sys-
tem without further input from the study team. In addition 
to the HIV testing intervention, participants in the HIV/TB 
arm received TB screening using digital chest x-ray (DCXR), 
interpreted by computer-aided diagnosis software (CAD4TB 
v5). Participants with DCXRs showing a high probability of 
TB (CAD4TB score ≥45) had a sputum sample collected, 
which was tested at the study clinic using GeneXpert MTB/
Rif; those with microbiologically confirmed TB were linked 
to clinic TB treatment services.
Between 12th February 2019 and 16th September 2019, cost 
data were collected from 219 consecutive PROSPECT trial 
participants during their outcome assessment visits at Bangwe 
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Health Centre, conducted approximately on the 56th day after 
recruitment. Due to time and resource constraints, this was 
a convenience sample.
Data collection
An interviewer-administered questionnaire25, adapted from the 
STOP TB patients’ cost tool26, was used to estimate the direct 
medical, direct non-medical and indirect costs incurred by par-
ticipants and their household members when accessing TB 
diagnostic and medical services during the 56 day PROSPECT 
follow-up period. Information was obtained on the direct and 
indirect costs incurred from accessing healthcare services deliv-
ered at the study clinic, any government hospital that they 
attended and were admitted to, and through any private 
healthcare provider. Private healthcare providers included pri-
vate clinics, pharmacies, and traditional healers. For all health-
care provider visits, we recorded the number of visits made, 
time spent travelling to and waiting at the facility, and any 
out-of-pocket expenditures (transport costs, food etc). Informa-
tion on the amount of time the patient and guardian stopped 
taking part in any income generating activities due to the 
patient’s illness or care-seeking activities was also systematically 
recorded.
As self-reported expenditure was used, this study was sub-
ject to recall bias. However, the extent of this was minimised as 
the period under evaluation was restricted to the PROSPECT 
trial’s study period, 56 days. Moreover, all questions were 
delivered in the local language, and care was taken to ensure 
participants fully understood the question. Additionally, 
each participant was questioned the same way, regardless of 
intervention group, to avoid responses being influenced.
Costs and data analysis
Data were analysed using Stata v14 (College Station, Texas, 
US). All monetary variables were converted from the Malawian 
Kwacha (MWK) to the United States Dollar (US$) using the 
market exchange rate as of the 12th of February 2019 as 
determined by the Reserve Bank of Malawi (MWK739.8089/
US$127).
We estimated direct medical, direct non-medical and indirect 
costs. Direct medical costs consisted of any charges incurred 
when seeking care from a private healthcare provider. Malawians 
do not pay to access government health services. Although, 
it is possible that patients accessing these services may incur 
informal or under-the-counter medical charges, these costs 
were not included28. Direct non-medical costs included out of 
pocket costs (e.g. transportation, food) incurred whilst seeking 
care29,30. To estimate the indirect cost, the human capi-
tal approach was used. This entailed valuing the patient’s or 
guardian’s time with their estimated productive output, based on 
their pre-illness reported income29. Income groups were created 
by categorising participants into income terciles based on their 
annual household income (low, middle, and high income).
Descriptive statistics were used to summarise the data and to 
determine the distribution of key participant characteristics 
within each trial arm. We used the arithmetic mean and stand-
ard error to summarise the direct and indirect costs incurred 
by participants31,32. The mean costs were stratified by patient 
characteristics and trial arms.
We calculated the mean difference in direct and indirect 
costs between the intervention arms and the standard of care. 
As the cost data was skewed, we used non-parametric boot-
strap methods to derive 95% confidence intervals for the mean 
cost differences between categories31,33. Additionally, we 
calculated the percentage of participants whose households’ 
experienced catastrophic care-seeking costs. Participants were 
considered to have catastrophic costs if their total costs exceeded 
20% of their annual household income20,30,34. Catastrophic costs 
were calculated for those with complete household income data. 
Including those without complete household income data would 
lead to an overestimation of the proportion of participants fac-
ing catastrophic costs, as their household income may have 
been underestimated. We assumed that the missing data was 
missing completely at random.
Generalised linear regression models (GLM) with a gamma dis-
tribution and log link were used to investigate the association 
between trial interventions and the total cost incurred. Using 
GLMs we examined whether the costs varied by patient charac-
teristics with the likelihood ratio test. The modified Park test 
was used to ensure the models were specified appropriately35–37.
Ethical approval
Ethical approval was received from the University of 
Malawi- College of Medicine Research Ethics Committee 
and from the Ethics Review Board of the Liverpool School of 
Tropical Medicine. All participants provided written informed 
consent. If illiterate, participants were asked to provide a 
witnessed thumbprint.
Results
Of the 1320 participants that completed the PROSPECT 
trial’s 56 day follow up period, 219 participants were recruited 
to this study38. The main reasons for non-participation 
included the study’s time and resource constraints. Aside from 
age, individuals included in the study did not differ from the 
PROSPECT participants that did not take part in our study 
(Table 1).
Table 2 shows participant characteristics stratified by trial arm. 
Of the 219 participants, just over half were female (52.5%). 
Across the three arms, most of the participants were below the 
age of 35 years. A large proportion (71.7%) took part or had 
taken part in an income generating activity during the 12 months 
prior to this study. Additionally, 62.6% of the participants’ 
households had more than one income earner. Median house-
hold income was US$51.36 (IQR: US$27.03, US$81.10) per 
month.
During the PROSPECT trial’s 56 day follow up period, three 
(1.4%) out of the 219 participants were admitted into a health 
facility and five (2.3%) participants had initiated TB treatment. 
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Sex Male 578 (43.8%) 104 (18.0%) 474 (82.0%)
0.23
Female 742 (56.2%) 115 (15.5%) 627 (84.5%)
Age in years 18–24 394 (29.9%) 58 (14.7%) 336 (85.3%)
0.02
25–34 393 (29.8%) 76 (19.3%) 317 (80.7%)
35–44 291 (22.1%) 35 (12.0%) 256 (88.0%)
≥45 242 (18.3%) 50 (20.7%) 192 (79.3%)
Marital status Single (never married) 205 (15.7%) 32 (15.6%) 173 (84.4%)
0.44
Married/cohabiting 893 (68.2%) 148 (16.6%) 745 (83.4%)
Separated/ divorced 137 (10.5%) 29 (21.2%) 108 (78.8%)
Widower/ widow 74 (5.7%) 10 (13.5%) 64 (86.5%)
Education Never been to school 157 (11.9%) 20 (12.7%) 137 (87.3%)
0.29
Primary school 610 (46.2%) 113 (18.5%) 497 (81.5%)
Attended secondary school (no MSCE) 357 (27.1%) 56 (15.7%) 301 (84.3%)
Has at least an MSCE 196 (14.9%) 30 (15.3%) 166 (84.7%)
HIV status at baseline HIV positive 262 (19.9%) 38 (14.5%) 224 (85.5%)
0.34HIV negative 968 (73.3%) 162 (16.7%) 806 (83.3%)
Never tested 90 (6.8%) 19 (21.1%) 71 (78.9%)
Trial arm SOC 420 (31.8%) 73 (17.4%) 347 (82.6%)
0.87Optimised HIV screening 450 (34.1%) 73 (16.2%) 377 (83.8%)
Optimised HIV & TB screening 450 (34.1%) 73 (16.2%) 377 (83.8%)
Refers to the participants that completed the PROSPECT trial’s 56 day follow up period (N=1320).
SOC: Standard of care
HIV: Human Immunodeficiency Virus
TB: Tuberculosis
On average, participants made 1.63 (SD: 0.91) visits to a 
healthcare provider.
Patient costs across all trial arms
The mean total cost incurred by all participants seeking diag-
nostic care for TB symptoms during the PROSPECT study 
follow-up period was US$12.11 (SE:1.86) (Table 3). Overall, 
the mean total direct cost was US$3.64 (SE:0.38) and the mean 
indirect cost was US$8.47 (SE:1.66). On average, men incurred 
higher total costs (US$14.90, SE:3.34) compared to women 
(US$9.58, SE:1.83, p=0.001). Costs were also shown to vary 
with age (p<0.001). Participants aged between 25 and 44 
years faced the highest indirect cost (US$14.07, SE:5.84) and 
total cost (US$16.61, SE:5.97) compared to other age groups. 
The total cost also varied by education (p<0.001) and income 
(p<0.001) levels. Participants that have never been to school 
had the lowest cost (US$8.00, SE:2.46) and costs increased 
with increasing income group.
Patient costs in the SOC arm
Shown in Table 4 are the mean total cost faced by participants 
under the SOC arm, which was US$13.18 (SE:2.79). These par-
ticipants incurred direct costs amounting to US$4.29 (SE:0.74) 
and an indirect cost of US$8.90 (SE:2.54).
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Table 2. Participant characteristics.
Characteristic Total 
N=219





Optimised HIV & 
TB screening 
N=73
Sex Male 104 (47.5%) 34 (46.6%) 34 (46.6%) 36 (49.3%)
Female 115 (52.5%) 39 (53.4%) 39 (53.4%) 37 (50.7%)
Age in years 18–24 58 (26.5%) 23 (31.5%) 20 (27.4%) 15 (20.6%)
25–34 76 (34.7%) 21 (28.8%) 30 (41.1%) 25 (34.3%)
35–44 35 (16.0%) 13 (17.8%) 9 (12.3%) 13 (17.8%)
≥45 50 (22.8%) 16 (21.9%) 14 (19.2%) 20 (27.4%)
Marital status Single (never 
married)
32 (14.6%) 11 (15.1%) 12 (16.4%) 9 (12.3%)
Married/cohabiting 148 (67.6%) 51 (69.9%) 47 (64.4%) 50 (68.5%)
Separated/ divorced 29 (13.2%) 7 (9.6%) 11 (15.1%) 11 (15.1%)
Widower/ widow 10 (4.6%) 4 (5.5%) 3 (4.1%) 3 (4.1%)
Education Never been to school 20 (9.1%) 4 (5.5%) 9 (12.3%) 7 (9.6%)
Primary 113 (51.6%) 37 (50.7%) 33 (45.2%) 43 (58.9%)
Attended secondary 
school (no MSCE)
56 (25.6%) 21 (28.8%) 20 (27.4%) 15 (20.6%)
Has at least an MSCE 30 (13.70%) 11 (15.1%) 11 (15.1%) 8 (11.0%)
Takes part in an 
income generating 
activity 
157 (71.7%) 50 (68.5%) 57 (78.1%) 50 (68.5%)
Mean household size 
(SD)
4.4 (2.1) 4.8 (2.2) 4.2 (1.9) 4.3 (2.0)
Households with >1 
income earner 
137 (62.6%) 48 (65.8%) 41 (56.2%) 48 (65.8%)
Median monthly 
household income - 
2019 US Dollars (IQR)*
51.36 (27.03, 81.10) 51.91 (27.03, 81.10) 54.07 (33.79, 91.92) 40.55 (16.22, 81.10)
HIV status at baseline 
HIV positive 38 (17.4%) 10 (13.7%) 14 (19.2%) 14 (19.2%)
HIV negative 162 (74.0%) 57 (78.1%) 52 (71.2%) 53 (72.6%)
Never tested 19 (8.7%) 6 (8.2%) 7 (9.6%) 6 (8.2%)
Admitted to a 
health facility during 
PROSPECT follow up
3 (1.4%) 1 (1.4%) 1 (1.4%) 1 (1.4%)
Initiated TB treatment 
during PROSPECT trial 
follow up
5 (2.3%) 2 (2.7%) 1 (1.4%) 2 (2.7%)
HIV: Human Immunodeficiency Virus
TB: Tuberculosis
SD: Standard deviation
US Dollars: United States Dollars
MSCE: Malawi School Certificate of Education (attained after completing secondary school)
IQR: Interquartile range
*US$1= Malawi Kwacha 739.8089 as of 12/02/19
39 participants had missing income data.
Page 6 of 13
Wellcome Open Research 2021, 6:153 Last updated: 02 JUL 2021




















for mean total 
cost)
All participants 1.00 (0.13) 2.64 (0.32) 3.64 (0.38) 8.47 (1.66) 12.11 (1.86)
Sex Male 0.80 (0.17) 2.44 (0.39) 3.24 (0.44) 11.67 (3.08) 14.90 (3.34)
Female 1.18 (0.19) 2.83 (0.50) 4.01 (0.60) 5.57 (1.44) 9.58 (1.83) 0.001
Age (years) 18–24 1.12 (0.25) 2.45 (0.40) 3.57 (0.53) 4.51 (1.13) 8.08 (1.42)
25–34 1.11 (0.23) 3.90 (0.81) 5.01 (0.91) 11.24 (3.68) 16.25 (4.30)
35–44 1.04 (0.41) 1.49 (0.29) 2.54 (0.53) 14.07 (5.84) 16.61 (5.97)
≥45 0.67 (0.21) 1.75 (0.37) 2.42 (0.49) 4.91 (1.50) 7.33 (1.62) <0.001
Marital status Single (never married) 0.96 (0.33) 3.55 (1.14) 4.51 (1.37) 8.09 (4.06) 12.59 (5.32)
Married/cohabiting 1.07 (0.17) 2.61 (0.39) 3.69 (0.46) 9.13 (2.21) 12.81 (2.43)
Separated/ divorced 0.82 (0.31) 2.02 (0.44) 2.84 (0.58) 5.08 (1.81) 7.92 (1.96)
Widower/ widow 0.57 (0.35) 1.96 (0.66) 2.53 (0.96) 9.71 (7.39) 12.24 (7.15) 0.16
Education Never been to school 0.66 (0.35) 2.22 (0.56) 2.88 (0.81) 5.12 (2.31) 8.00 (2.46)
Primary school 0.93 (0.18) 1.96 (0.25) 2.90 (0.34) 5.67 (1.27) 8.56 (1.38)
Attended secondary 
school (no MSCE)
1.01 (0.24) 3.82 (0.94) 4.83 (1.01) 13.62 (5.34) 18.46 (5.86)




Lowest tertial 0.90 (0.19) 2.35 (0.57) 3.25 (0.64) 2.70 (1.07) 5.96 (1.34)
Middle tertial 0.93 (0.22) 2.50 (0.44) 3.43 (0.55) 7.00 (2.41) 10.43 (2.63)
Highest tertial 1.19 (0.28) 3.11 (0.65) 4.30 (0.76) 16.44 (4.29) 20.74 (4.84) <0.001
Direct medical costs included any charges incurred when seeking care from a private healthcare provider.
Direct non-medical costs consisted of transport, food, and other costs non-related to medical care
US Dollars: United states dollars
US$1= MWK739.8089 as of 12/02/19
SE: Standard error
MSCE: The Malawi School Certificate of Education (attained after completing secondary school)
*likelihood ratio test
39 participants had missing income data.
Patient costs in the intervention arms
Participants in the HIV arm incurred a mean total cost of 
US$10.76 (SE:2.56). This was composed of a total direct 
cost amounting to US$3.55 (SE:0.68) and an indirect cost of 
US$7.21 (SE:2.01). With regards to the HIV/TB arm, the mean 
total cost was US$12.38 (SE: 4.13). The mean total direct and 
indirect cost amounted to US$3.09 (SE:0.52) and US$9.28 
(SE:3.79) (Table 4).
Composition of costs
Across all intervention groups, a large proportion of the aver-
age total cost was composed of indirect costs (69%). The indi-
rect cost composed 67.5%, 67.0%, and 75.0% of the total cost 
in the SOC, HIV and HIV/TB arms, respectively. Among the 
direct costs, transportation costs accounted for the greatest 
share of the total cost (SOC arm: 15.7%; HIV arm: 18.8%; and 
HIV/TB arm: 13.9%) (Figure 1 & Figure 2).
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Table 4. Costs associated with seeking TB diagnostic care by intervention arm (2019 US Dollars).
Mean (SE) Mean difference (95% CI) *
SOC HIV HIV/TB HIV vs SOC HIV/TB vs SOC.
Direct medical cost $1.34 (0.27) $0.80 (0.19) $0.86 (0.21) -0.54 (-1.17, 0.09) -0.48 (-1.14, 0.18)
Direct non-medical cost $2.95 (0.63) $2.75 (0.55) $2.23 (0.47) -0.20 (-1.84, 1.44) -0.72 (-2.27, 0.84)
Total direct cost $4.29 (0.74) $3.55 (0.68) $3.09 (0.52) -0.74 (-2.62, 1.14) -1.20 (-2.87, 0.49)
Indirect cost $8.90 (2.54) $7.21 (2.01) $9.28 (3.79) -1.69 (-8.15, 4.78) 0.38 (-8.64, 9.41)
Total cost $13.18 (2.79) $10.76 (2.56) $12.38 (4.13) -2.42 (-9.75, 4.90) -0.80 (-10.81, 9.20)
Direct medical costs included any charges incurred when seeking care from a private healthcare provider.
Direct non-medical costs consisted of transport, food, and other costs non-related to medical care.
US Dollars: United States DollarsUS$1= Malawi Kwacha 739.8089 as of 12/02/19
SOC: Standard of care arm
HIV: Optimised Human Immunodeficiency Virus (HIV) screening and linkage to care arm.
HIV/TB: Optimised tuberculosis (TB) and HIV screening and linkage to care arm.
SE: Standard error
CI: Confidence interval*Bootstrapped estimate
Figure 1. Average costs by trial arm. SOC: Standard of care arm HIV: Optimised Human Immunodeficiency Virus (HIV) screening and 
linkage to care arm. HIV/TB: Optimised tuberculosis (TB) and HIV screening and linkage to care arm. US$: United States Dollar US$1= Malawi 
Kwacha 739.8089 as of 12/02/19.
Comparison of costs
Compared to the SOC arm, the total cost faced by participants 
seeking healthcare for TB related symptoms was US$2.42 lower 
(95% CI: -US$9.75, US$4.90) in the HIV arm, and US$0.80 
lower (95% CI: -US$10.81, US$9.20) in the HIV/TB arm. 
In comparison to the SOC arm, total direct costs were 
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Figure 2. Composition of costs by trial arm. SOC: Standard of care arm HIV: Optimised Human Immunodeficiency Virus (HIV) screening 
and linkage to care arm. HIV/TB: Optimised tuberculosis (TB) and HIV screening and linkage to care arm. US$: United States Dollar US$1= 
Malawi Kwacha 739.8089 as of 12/02/19.
US$0.74 (95%CI: -US$2.62, US$1.14) lower in the HIV arm 
and US$1.20 (95% CI: -US$2.87, US$0.49) lower in the HIV/
TB arm. Indirect costs were US$1.69 (95% CI: -US$8.15, 
US$4.78) lower for those in the HIV arm compared to the 
SOC arm. The indirect cost faced by participants in the HIV/
TB arm was slightly higher (US$0.38, 95% CI: -US$8.64, 
US$9.41) than the SOC arm (Table 4).
Illustrated in Table 5, both models show that the participants 
who received optimised diagnostic interventions faced lower 
costs as compared to the current standard of care. In the fully 
adjusted model, adjusting for age, sex, marital status, educa-
tion, income and HIV status, the mean total cost under the HIV 
arm was 23% (ratio: 0.77, 95% CI: 0.51, 1.19) lower than the 
SOC arm, although this difference was not statistically sig-
nificant (p=0.24). The mean total cost incurred by those in the 
HIV/TB arm was 15% (ratio:0.85, 95%CI: 0.53, 1.37) lower 
than the SOC arm (p=0.51).
Economic burden and catastrophic costs
Of the 180 participants with complete household income data, 
the total cost comprised 5.6% of participants’ average annual 
household income. In this study, nine (5.0%) participants 
incurred catastrophic costs (Table 6). Within each group, three 
(4.8%), three (5.1%), and three (5.1%) participants in the SOC 
arm, HIV arm and HIV/TB arm experienced catastrophic 
costs, respectively. Women carried a higher economic burden 
as 8.3% of their income was taken up by care-seeking costs, 
for men this was 3.0%. The economic burden was also higher 
among those aged 45 years and over (11.1%) as compared 
to other age groups. Those with a primary education faced 
a higher burden with costs being 7.7% of annual household 
income. The economic burden faced by patients decreased with 
increasing income, with the lowest income group facing the 
greatest burden (15.1%).
Discussion
Within the context of a three-arm randomised trial of novel 
TB diagnostics in Malawi, we set out to investigate the costs 
faced by patients when seeking care with TB symptoms and 
whether optimising the diagnostic pathway would reduce 
these costs. The main finding was that participants seek-
ing diagnosis and care with TB symptoms incurred substan-
tial costs, with 5.0% of participants incurring catastrophic costs. 
Within the SOC arm, 4.8% of participants had costs that were 
catastrophic. This is despite the absence of user fees and 
healthcare services being provided for free in primary health-
care facilities in Malawi. Although the costs incurred under 
the optimised diagnostic interventions were slightly lower 
than the current standard of care, the differences were not 
statistically significant.
According to existing literature, optimising the diagnos-
tic pathway to reduce the time to diagnosis and treatment 
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Table 5. Multivariable analysis exploring the relationship between trial 
arm and mean total cost.
Model 1 Model 2 
Trial arm Ratio of mean total 
cost (95% CI) 
P-value Ratio of mean total 
cost (95% CI) 
P-value 
SOC Ref - - Ref - -
HIV 0.82 (0.50, 1.35) 0.44 0.77 (0.51, 1.19) 0.24
HIV/TB 0.82 (0.47, 1.45) 0.50 0.85 (0.53, 1.37) 0.51
Model 1: adjusted for age and sex.
Model 2: additionally, adjusted for marital status, educational attainment, total household 
income tertial and HIV status at baseline.
SOC: Standard of care arm
HIV: Optimised Human Immunodeficiency Virus (HIV) screening and linkage to care arm.
HIV/TB: Optimised tuberculosis (TB) and HIV screening and linkage to care arm.
CI: Confidence interval; Ref: reference category
Findings from generalized linear models with gamma distribution and log link.
initiation should lead to a reduction in the costs faced by 
patients as the number of visits required to obtain a diagnosis 
reduces13–15,39. The lack of evidence for this association in this 
study may be due to the participants making approximately 
two visits to a healthcare provider, on average. This is further 
compounded by most of the participants not being diagnosed 
with TB (97.7%), as these patients do not require multiple vis-
its to healthcare providers as compared to those diagnosed with 
TB disease. Altogether, this meant that the interventions exam-
ined in this study had a limited impact on the income loss from 
spending time seeking healthcare, and the cost of transport 
of which were the main cost drivers found in this study.
However, given that most patients did not have TB dis-
ease, the substantial care-seeking costs further substantiates 
the need for optimised diagnostic interventions to reduce the 
time and healthcare visits taken to obtain a diagnosis and ini-
tiate treatment In line with previous studies conducted in 
sub-Saharan Africa14–16,40–42, this study found that a large pro-
portion (69.9%) of the total cost was due to income loss. 
For patients with TB disease, these costs can be detrimen-
tal as they often undergo extensive waiting times and multiple 
visits to healthcare providers when seeking diagnosis and 
treatment. The direct medical expenses that can be incurred 
have been minimised by the public health services in Malawi 
being provided free of charge; and most patients not seek-
ing additional healthcare from private health facilities. There-
fore, efforts should be made towards minimising the income 
losses by patients with TB disease through reducing the time and 
number of visits needed to obtain a diagnosis.
A large share of the direct cost was the cost of transport. This 
has also been shown in previous studies and is seen as an indi-
cation of TB diagnostic services not being easily accesible13,14,39. 
Although optimising the TB diagnostic and treatment path-
ways may reduce the costs incurred from transportation as 
fewer visits are made before receiving a diagnosis, the effec-
tiveness of these interventions may be limited if healthcare 
services are inaccessible to most Malawians. This implies that 
alongside optimising the TB diagnostic pathway, efforts towards 
ensuring universal access to healthcare should be put in place. 
Such solutions can include community-based interventions. 
Aside from increasing coverage of TB health services, previ-
ous studies have shown that such interventions can reduce the 
costs faced by patients43,44. This is primarily due to these inter-
ventions bringing services closer to the community therefore 
inducing savings on transportation costs and possible user from 
private health facilities44.
Alongside optimised diagnosis pathways, social protec-
tion interventions should be put in place. The findings of this 
study show that similar proportions (4.8% to 6.8%) of patients 
incurred catastrophic costs regardless of intervention group. 
Additionally, the economic burden faced by patients varied by 
socio-demographic characteristics revealing that certain groups 
are more vulnerable to impoverishment. Of importance, 
it was demonstrated that despite having lower costs, those in 
the lowest income group faced the highest economic burden. 
Moreover, this group had the highest proportion of individu-
als facing catastrophic costs. This has also been demonstrated in 
previous studies conducted in Malawi’s rural areas as the pro-
portion of income consumed by care-seeking costs rose with 
decreasing wealth16. This is similarly shown among women, 
as although having lower costs as compared to men, their eco-
nomic burden was much higher. The high economic burden 
experienced by these groups is regardless of healthcare being 
provided free of charge and costs being comparably lower. This 
signifies the need for social protection policies that can ease 
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All participants 180 (100%) 801.52 (53.92) 5.6% 9 (5.0%)
Trial arm SOC 62 (34.4%) 833.69 (82.87) 4.0% 3 (4.8%)
HIV 59 (32.8%) 781.28 (93.14) 6.3% 3 (5.1%)
HIV/TB 59 (32.8%) 787.98 (105.25) 6.7% 3 (5.1%)
Sex Male 90 (50%) 921.11 (70.18) 3.0% 2 (2.2%)
Female 90 (50%) 681.94 (80.30) 8.3% 7 (7.8.%)
Age (years) 18–24 41 (22.8%) 927.19 (131.64) 1.0% 0
25–34 69 (38.3%) 892.83 (95.97) 3.3% 1 (1.5%)
35–44 29 (16.1%) 724.87 (107.86) 10.0% 4 (13.8%)
≥45 41 (22.8%) 576.42 (74.57) 11.1% 4 (9.8%)
Marital status Single (never married) 19 (10.6%) 1266.25 (267.36) 0.8% 0
Married/cohabiting 129 (71.7%) 830.52 (57.31) 2.6% 2 (1.6%)
Separated/ divorced 23 (12.8%) 382.45 (84.98) 19.0% 4 (17.4%)
Widower/ widow 9 (5.0%) 475.80 (172.0) 26.1% 3 (33.3%)
Education Never been to school 16 (8.9%) 560.11 (111.78) 7.6% 1 (6.3%)
Primary 97 (53.9%) 686.34 (56.47) 7.7% 6 (6.2%)
Attended secondary 
school (no MSCE)
43 (23.9%) 932.79 (146.62) 2.7% 2 (4.7%)




Lowest tertial 55 (30.6%) 226.97 (19.24) 15.1% 8 (14.5%)
Middle tertial 69 (38.3%) 620.63 (14.14) 1.6% 1 (1.5%)
Highest tertial 56 (31.1%) 1588.70 (108.89) 1.3% 0
* US$1= MWK739.8089 as of 12/02/19
SOC: Standard of care arm
HIV: Optimised Human Immunodeficiency Virus (HIV) screening and linkage to care arm.
HIV/TB: Optimised tuberculosis (TB) and HIV screening and linkage to care arm.
SE: Standard Error
MSCE: Malawi Secondary Certificate of Education
the financial burden faced by vulnerable households in Malawi 
when seeking healthcare.
We also found that the most economically active groups 
incurred the highest care-seeking costs. Firstly, men are shown 
to have higher costs. This is also true in studies conducted in 
other urban and rural areas of Malawi14,45. Individuals aged 
between 25 and 44 years experienced higher costs com-
pared to other age groups. In rural Malawi however, people 
aged 65 years and over incurred the highest direct cost when 
seeking care for a chronic cough45. It is possible that the 
individuals from that study may have had a relatively lower 
cost as compared to other groups if income loss were con-
sidered. In settings such as Malawi, males and those aged 
between 25 and 44 years are relatively more economically 
active. As a result, these groups will often have a greater loss 
of income when seeking healthcare14,46. This can deter such 
individuals from seeking healthcare. This can lead to adverse 
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health outcomes and have a negative impact on the strides made 
towards reducing the incidence of TB in Malawi. This fur-
ther suggests that optimised TB diagnosis interventions are 
likely to be more effective alongside social protection poli-
cies that ensure such groups are compensated for the time lost 
when seeking healthcare.
A limitation of this study was the use of self-reported income 
for the estimation of total indirect cost. The use of self-reported 
income in settings where the informal employment sector 
dominates is often unreliable and subject to non-response29,47. 
However, this approach was used because recent national 
income data was unavailable, and the calculation of consump-
tion expenditure was beyond the scope of this study. Moreo-
ver, there is uncertainty around which method provides the 
most accurate estimates in such settings47. This indicates the 
necessity for further research on comparing and determin-
ing appropriate methods for measuring household income in 
facility-based surveys taking place in such settings. Addition-
ally, findings of this study may have been subjected to recall 
bias. This can lead to inaccurate estimates of the costs faced by 
the patients. However, this method was the only feasible way 
of obtaining information that would lead to the estimation of 
the total cost faced by patients seeking diagnosis for acute 
symptoms of TB.
Although it can be assumed that the findings of this study 
can be generalised across Malawi, caution must be taken as 
the participants in this study may not fully be representative 
of Malawi. This is particularly true with regards to the costs 
faced by patients seeking care as the extent of these costs can 
vary geographically. Nonetheless, the study highlights that 
patients face costs that can be catastrophic when seeking 
care.
In conclusion, individuals seeking diagnostic care for TB symp-
toms in Blantyre, Malawi incurred high costs with patients 
experiencing catastrophic costs. The optimised TB diagnos-
tic interventions being investigated in the PROSPECT study, 
did not lead to a reduction in the costs faced by patients. For 
these interventions to make an impact, further efforts should 
be made towards ensuring that these interventions significantly 
reduce the indirect costs faced by patients. However, opti-
mised diagnostic strategies alone are not enough to ensure a 
significant reduction in the financial burden placed on house-
holds. Therefore, community-based interventions and social 
protection policies should be put in place to ensure the financial 




Figshare: Economic costs of accessing TB diagnostic serv-
ices in Malawi: an analysis of patient costs from a randomised 
controlled trial of computer-aided chest x-ray interpretation.
https://doi.org/10.6084/m9.figshare.14095569.v238.
This project contains the following underlying data and code:
–    01-Economic costs - generating variables: A STATA dofile 
containing the code needed to generate key variables 
for analysis.
–    02-Economic costs - stat and cost analysis: A STATA 
dofile containing the code needed to conduct the analysis 
and produce the tables and figures presented in this 
manuscript.
–    03: Economic costs_dataset: A de-identified dataset in 
CSV format, containing the data needed to conduct the 
analysis.
Extended data
Figshare: Economic costs of accessing TB diagnostic services 
in Malawi: questionnaires.
https://doi.org/10.6084/m9.figshare.14207327.v225.
This project contains the following extended data:
–    Questionnaire
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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